Endocrinology

Top Story

AMPK activator reduces glucose level in type 2 diabetes in phase 2a trial

November 18, 2017

A novel AMP-activated protein kinase activator showed glucose reduction and decreased cardiovascular risk factors in people with type 2 diabetes in a phase 2a trial, according to a press release from the drug’s developer.

The first-in-class drug (O304, Betagenon/Baltic Bio) activates AMP-activated protein kinase (AMPK), which regulates energy balance. By activating this protein, the researchers aimed to prevent type 2 diabetes and cardiovascular disease.

In the Journals

Nearly 1 in 7 patients with diabetes have poor glycemic control

November 17, 2017
About one in seven patients with diabetes had poor glycemic control between 2007 and 2014 despite an increase in the frequency of self-reported testing and patient…
In the Journals Plus

Patients with Addison's disease show no increase in adipose tissue

November 17, 2017
Although patients with Addison’s disease who were treated with glucocorticoids demonstrated increased cortisol exposure, they did not have increased levels of
In the Journals PlusPerspective

Heart failure strongest predictor of poor survival in type 2 diabetes

November 17, 2017
Older adults with type 2 diabetes are at increased risk for death from cardiovascular complications, with the strongest associations found between survival and heart…
In the Journals Plus

Glycemic control, drug regimen interaction influence mortality risk in type 2 diabetes

November 17, 2017
Adults with type 2 diabetes who achieve low HbA1c targets may have an increased risk for death, particularly when treated with regimens associated with hypoglycemia…
More Headlines »
CME

Best of Obesity Forum® 2017

This activity is supported by an educational grant from Novo Nordisk, Inc.

The incidence of obesity has increased dramatically over the past 20 years and is considered to be an epidemic in the…
More »
Video
Meeting News

VIDEO: Anabolic agents should be prescribed early for high-risk osteoporosis

October 17, 2017
More »
Resource Centers
ObesityWeek

ObesityWeek

CDR CME CNE CPE

Back to the Future: Clinical Experience with and Access to Lipid-Lowering Agents of the Past, Present, and Future

This activity is supported by educational funding provided by Amgen and Sanofi US and Regeneron Pharmaceuticals.

With each passing year we gain new insight and understanding around the clinical utilization of lipid-lowering…
More »
Current Issues
View the Current Issue
Advertisement
Advertisement